Please assess the completion status of the following clinical trial:

Trial Title: Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the criteria for manic or mixed episodes according to the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) and have a diagnosis of 294.4x Bipolar I Disorder, Most Recent Episode Manic or 296.6x Bipolar I Disorder, Most Recent Episode Mixed.~* Have a total score on the Young Mania Rating Scale (YMRS) of at least 20 at Visit 1 and Visit 2.~Exclusion Criteria:~* Have received an antidepressant or a psychostimulant within 5 days prior to Visit 1.~* The duration of the current episode is more than 90 days at Visit 1.~* Have a history or a diagnosis of diabetes mellitus.~* Have received any psychotropic medication within 2 days prior to Visit 2 (except for benzodiazepines).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine (Type: EXPERIMENTAL): olanzapine: 5 to 20 mg per day for 6 weeks
- Haloperidol (Type: ACTIVE_COMPARATOR): haloperidol: 2.5 to 10 mg per day for 6 weeks
- Placebo (Type: PLACEBO_COMPARATOR): placebo for 3 weeks, then olanzapine 5 to 20 mg per day for 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).